MedTrace Logo

The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health

NCT07760506 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-08-12

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if Quercefit® or Ubiqsome™ can improve markers of healthy aging, blood sugar control, and heart health in older adults. It will also learn about the safety of these supplements.

The main questions it aims to answer are:

1. Do Quercefit® or Ubiqsome™ improve blood sugar, cholesterol, and markers of aging compared to a placebo?
2. What side effects, if any, do participants have while taking these supplements?

Researchers will compare Quercefit® (500 mg/day), Ubiqsome™ (300 mg/day), and a placebo (a look-alike capsule with no active ingredient).

Participants will:

1. Take their assigned capsules (Quercefit®, Ubiqsome™, or placebo) twice daily for 12 weeks
2. Go to a preferred clinic at the start and end of the study for a fasting blood draw

Complete at-home tests:
3. Grip strength testing (using a device mailed to them)
4. Online surveys about fatigue and quality of life
5. Report any side effects and keep track of supplement use

Conditions

  • Healthy Aging
  • Inflammaging
  • Metabolic Health
  • Quercetin
  • Coenzyme Q10

Interventions

DIETARY_SUPPLEMENT

Quercetin (dietary supplement)

Natural compound found in foods like apples and onions that may help reduce inflammation and support overall health.

DIETARY_SUPPLEMENT

Coenzyme Q10

Substance made by the body that helps produce energy in cells and also acts as an antioxidant to support heart and overall health.

DIETARY_SUPPLEMENT

Rice Flour

An inert carbohydrate used as the control treatment

Sponsors & Collaborators

  • Applied Science & Performance Institute

    lead INDUSTRY

Principal Investigators

  • Jacob Wilson, PhD · The Applied Science and Performance Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2028-08-31
Completion
2028-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07760506 on ClinicalTrials.gov